FIELD TRIALS OF G.S. 2989 331 76X6 per cent. cure of trachoma was recorded respectively during treatment (Table II) . After four months of follow-up the cure rate increased to 79 5, 88X8, and 77X9 per cent. (Table II) . The effect of G.S. 2989 (0.25 per cent. and I 0 per cent.) on the associated conjunctivitis was found to be more or less identical with oxytetracycline (I 0 per cent.) (Table III) . However, G.S. 2989 (1 0 per cent.) was more effective in preventing the relapse and re-infection during the follow-up period (Table III) . At present the sheet anchor of the mass campaigns being waged against trachoma and associated infections in endemic countries is the intermittent treatment by broadspectrum antibiotics. Encouraging results (with an accepted degree of failures) from the use of oxytetracycline and tetracycline have been reported from time to time (Bietti, 1951; Mitsui and Tanaka, 1951; Naccache, 1953; Pavkovic-Bugarski and Cvetojevic, 1954; Tsutsui, 1959) . However, clinical analysis of newer antibiotics is constantly being carried out in order to find a cheap, more effective, and easily acceptable drug for mass treatment. G.S. 2989 is definitely effective against trachoma and allied infections as is evident from Tables 11 and III. The cure rates in Groups A, B, and C were found to be 74-7, 76-3, and 76-6 per cent. respectively. G.S. 2989 (0-25 per cent.), G.S. 2989 (1 0 per cent.), and oxytetracycline (1 0 per cent.) did not show any significant difference one from the other (X2 = 0x02283 for 2 degrees of freedom). Differences in the three groups were re-tested taking two at a time. No group showed superiority over the other regarding the cure rate for trachoma.
Re-examination of cases after four months' cessation of treatment revealed an increase in cure rates in all the three groups (see Table II ). This finding is contrary to our earlier observation (Nema and others, 1964) and is in agreement with the claims of Bietti (1955) and Maxwell-Lyons (1955) , who recorded a higher cure rate of trachoma after three to four months of cessation of treatment. The probable explanation of this variation lies in the different treatment schedules adopted by the authors for the two trials. Moreover, in a mass campaign with overall coverage of active cases of trachoma, there are fewer chances of re-infection than in individual treatments, where the home and community produce active cases which may act as sources of re-infection. The percentage cure after four months in Group B was fairly high (88-8 per cent.), which significantly differed from Group C (77 9 per cent.). The cure rate in Group B compared with Group A was not statistically different. Thus it was inferred that G.S. 2989 (0 25 per cent. and 1 0 per cent.) and oxytetracycline (1 0 per cent.) were equally effective soon after treatment, but that G.S. 2989 (1 0 per cent.) was superior during the follow-up period.
Similarly, the drugs in all the three groups were found to be more or less equally effective against associated conjunctivitis at the cessation of treatment. Cases of relapse or re-infection were noticed at the final examination in all three groups, but the rate was comparatively low in the G.S. 2989 (I 0 per cent.) group. Therefore, it is concluded that G.S. 2989 (I 0 per cent. in oil suspension) is a useful drug in the therapy of trachoma and allied infections, particularly in checking the relapses of conjunctivitis. Summary A new antibiotic, G.S. 2989 (0-25 per cent. and 1 0 per cent. in oil suspension) was evaluated against trachoma and allied infections in 240 trachomatous children. The drug was as effective as oxytetracycline at the cessation of treatment, but G.S. 2989 (I 0 per cent. in oil suspension) showed better results in the cure of trachoma, as well as in preventing the re-infection and relapses of associated conjunctivitis after four months of follow-up.
